Protein Kinase Inhibitors: all 15,278 studies that test it
Page 121 of 153. Open to participants first (2,558), then studies with results posted, then the rest; newest registration first within each.
- A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib TrialCompletedNCT02057380Phase 2
- A Study of ARRY-371797 in Patients With LMNA-Related Dilated CardiomyopathyCompletedNCT02057341Phase 2
- Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab TreatmentCompletedNCT02056587Phase 4
- Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney DiseaseStatus unknownNCT02055079Phase 3
- A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast CancerCompletedNCT02053636Phase 2
- Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb StudyTerminatedNCT02052193Phase 2
- A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck CancerCompletedNCT02051751Phase 1
- MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic FunctionTerminatedNCT02050815Phase 1
- MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02049801Phase 1
- Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaCompletedNCT02049541Phase 1
- Study of the Combination of Tivantinib Plus Pemetrexed and CarboplatinCompletedNCT02049060Phase 1/2
- Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With ChemotherapyCompletedNCT02049047Phase 2
- Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic CancerWithdrawnNCT02048943Phase 1
- Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.CompletedNCT02048787Phase 1
- Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's DiseaseCompletedNCT02048618Phase 2
- A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and LymphomasCompletedNCT02048488Phase 1/2
- Japanese BAY1000394 Monotherapy Phase I StudyCompletedNCT02047890Phase 1
- To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male VolunteersCompletedNCT02046850Phase 1
- Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)WithdrawnNCT02044601Phase 1/2
- Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR MutationCompletedNCT02044328Phase 2
- MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal CancerCompletedNCT02041481Phase 1
- Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted ConditionsCompletedNCT02041273Phase 1
- A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line SettingStatus unknownNCT02041260Phase 2
- Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of AfuresertibCompletedNCT02040480Phase 1
- Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC PatientsCompletedNCT02040064Phase 1
- Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLCCompletedNCT02039336Phase 1/2
- An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid TumorsCompletedNCT02038673Phase 1
- Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLCStatus unknownNCT02037997Phase 2
- Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft RecipientsStatus unknownNCT02036554Phase 4
- Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung caStatus unknownNCT02036359Phase 2
- Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node MetastasesStatus unknownNCT02036086Phase 2
- DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).CompletedNCT02035813Phase 2
- Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02035527Phase 1
- Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With DocetaxelWithdrawnNCT02035124Phase 2
- Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1CompletedNCT02034981Phase 2
- A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung CancerWithdrawnNCT02034097Phase 2
- Icotinib Hydrochloride in Treating Patients With Advanced CancersWithdrawnNCT02033148Phase 1
- Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular LymphomaTerminatedNCT02031419Phase 1
- Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple MyelomaTerminatedNCT02030483Phase 1
- To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung CancerStatus unknownNCT02029209Phase 2/3
- A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)CompletedNCT02029157Phase 3
- Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL WomenCompletedNCT02028364Phase 2
- IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)WithdrawnNCT02028039Phase 2
- Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib AloneCompletedNCT02027961Phase 1
- High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable DiseaseStatus unknownNCT02027090Phase 2
- Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast CancerStatus unknownNCT02025712Phase 2
- Selumetinib in Combination With Gefitinib in NSCLC PatientsCompletedNCT02025114Phase 1/2
- Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic CancerStatus unknownNCT02024633Phase 1
- PALBOCICLIB + PD-0325901 for NSCLC & Solid TumorsCompletedNCT02022982Phase 1
- Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMDCompletedNCT02022540Phase 1
- Ursodeoxycholic Acid as Treatment for Polycystic Liver DiseaseCompletedNCT02021110Phase 2
- A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With GemcitabineCompletedNCT02018874Phase 1
- Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological MalignanciesCompletedNCT02017613Phase 1
- A Food Effect Phase I Study of the Volitinib in Healthy SubjectsCompletedNCT02017236Phase 1
- A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid LeukemiaCompletedNCT02016729Phase 1
- Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid TumorsTerminatedNCT02016534Phase 2
- Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain TumorsStatus unknownNCT02015728Not applicable
- Ruxolitinib in the Treatment of Chronic Lymphocytic LeukemiaCompletedNCT02015208Phase 1/2
- Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver MetastasisCompletedNCT02015169Phase 2
- Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)CompletedNCT02013648Phase 3
- A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02013219Phase 1
- Ublituximab + Ibrutinib in Select B-cell MalignanciesCompletedNCT02013128Phase 1/2
- A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC StudyStatus unknownNCT02013089Not applicable
- Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.TerminatedNCT02012231Phase 1
- Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung CancerStatus unknownNCT02009605Phase 2
- ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix CancerCompletedNCT02009579Phase 2
- Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of RecurrenceTerminatedNCT02009423Phase 3
- Randomized Phase II Study to Assess PD 0332991 in Breast CancerCompletedNCT02008734Phase 2
- Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal CancerCompletedNCT02008383Phase 1
- A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed ChondrosarcomasSuspendedNCT02008019Phase 2
- Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaActive, not recruitingNCT02007044Phase 2
- Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell MalignanciesCompletedNCT02006485Phase 1
- A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given, Relative To Capsule FormulationCompletedNCT02006277Phase 1
- Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)Status unknownNCT02006043Phase 2
- Phase I Clinical Study of Metatinib Tromethamine TabletCompletedNCT02004548Phase 1
- A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy SubjectsCompletedNCT02003547Phase 1
- Effect of Neomycin on the Pharmacokinetics of RegorafenibCompletedNCT02001909Phase 1
- Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR MutationStatus unknownNCT02001896Phase 3
- Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid LeukaemiaCompletedNCT02001818Phase 2
- A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma MalignanciesCompletedNCT02000934Phase 1
- Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.TerminatedNCT02000453Phase 1
- Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential ThrombocythemiaTerminatedNCT01998828Phase 2
- Everolimus Post Orthotopic Liver TransplantStatus unknownNCT01998789Phase 2
- Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung CancerCompletedNCT01998126Phase 1
- Continuation of TKI With or Without Chemotherapy Beyond Gradual ProgressionStatus unknownNCT01998061Phase 2
- Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)WithdrawnNCT01997255Phase 2
- Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal CancerCompletedNCT01996969Not applicable
- Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR MutationTerminatedNCT01996098Phase 3
- A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine TumorTerminatedNCT01994213Phase 2
- Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast CancerActive, not recruitingNCT01992952Phase 1/2
- Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or LymphomaTerminatedNCT01991938Phase 1
- MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)Active, not recruitingNCT01991379Phase 1/2
- A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.CompletedNCT01991184Phase 1
- Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate CancerActive, not recruitingNCT01990196Phase 2
- Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant MelanomaActive, not recruitingNCT01989585Phase 1/2
- Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT01988896Phase 1
- Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid TumorsCompletedNCT01985555Phase 1
- Combined Modality Treatment of Sarcomas of the ExtremitiesCompletedNCT01985295Phase 1
- A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast CancerCompletedNCT01983501Phase 1
- Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on VemurafenibCompletedNCT01983124Phase 2